Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Schattenberg
L Stump

Showing results (141-150 of 392) with videos related to

Pageof 40
Sort By:
Liver International : Official Journal of the International Association for the Study of the Liver|August 3, 2023
Hepatokine-based identification of fibrotic NASH and improved risk stratification in a multicentre cohort of NAFLD patientsMartin Franck, Katharina John, Sherin Al Aoua, et al.
Digestive Diseases (Basel, Switzerland)|July 5, 2017
Impact of Individual Components of the Metabolic Syndrome on the Outcome of Patients with Advanced Hepatocellular Carcinoma Treated with SorafenibChristian Labenz, Vera Prenosil, Sandra Koch, et al.
Hepatology (Baltimore, Md.)|April 1, 2022
An international survey on patterns of practice in NAFLD and expectations for therapies-The POP-NEXT projectVlad Ratziu, Quentin M Anstee, Vincent Wai-Sun Wong, et al.
Molecular Cancer Therapeutics|February 16, 2012
Therapeutic efficacy of CEP-33779, a novel selective JAK2 inhibitor, in a mouse model of colitis-induced colorectal cancerMatthew M Seavey, Lily D Lu, Kristine L Stump, et al.
Alimentary Pharmacology & Therapeutics|October 5, 2019
Raised serum Interleukin-6 identifies patients with liver cirrhosis at high risk for overt hepatic encephalopathyChristian Labenz, Gerrit Toenges, Yvonne Huber, et al.
Clinical and Translational Gastroenterology|June 23, 2020
Outcome Prediction of Covert Hepatic Encephalopathy in Liver Cirrhosis: Comparison of Four Testing StrategiesChristian Labenz, Gerrit Toenges, Jörn M Schattenberg, et al.
Plos One|March 19, 2016
The Impact of Liver Cell Injury on Health-Related Quality of Life in Patients with Chronic Liver DiseaseYvonne Alt, Anna Grimm, Liesa Schlegel, et al.
The American Journal of Gastroenterology|March 9, 2019
Development and Validation of a Prognostic Score to Predict Covert Hepatic Encephalopathy in Patients With CirrhosisChristian Labenz, Gerrit Toenges, Yvonne Huber, et al.
AIDS Care|September 26, 2001
Cost-effectiveness of prevention referrals for high-risk HIV-negatives in San FranciscoK S Heumann, R Marx, S J Lawrence, et al.
The Journal of Pharmacology and Experimental Therapeutics|October 31, 2007
Atrial antifibrillatory effects of structurally distinct IKur blockers 3-[(dimethylamino)methyl]-6-methoxy-2-methyl-4-phenylisoquinolin-1(2H)-one and 2-phenyl-1,1-dipyridin-3-yl-2-pyrrolidin-1-yl-ethanol in dogs with underlying heart failureChristopher P Regan, Laszlo Kiss, Gary L Stump, et al.
Pageof 40

Showing results (141-150 of 392) with videos related to

Sort By:
Pageof 40
Liver International : Official Journal of the International Association for the Study of the Liver|August 3, 2023
Hepatokine-based identification of fibrotic NASH and improved risk stratification in a multicentre cohort of NAFLD patientsMartin Franck, Katharina John, Sherin Al Aoua, et al.
Digestive Diseases (Basel, Switzerland)|July 5, 2017
Impact of Individual Components of the Metabolic Syndrome on the Outcome of Patients with Advanced Hepatocellular Carcinoma Treated with SorafenibChristian Labenz, Vera Prenosil, Sandra Koch, et al.
Hepatology (Baltimore, Md.)|April 1, 2022
An international survey on patterns of practice in NAFLD and expectations for therapies-The POP-NEXT projectVlad Ratziu, Quentin M Anstee, Vincent Wai-Sun Wong, et al.
Molecular Cancer Therapeutics|February 16, 2012
Therapeutic efficacy of CEP-33779, a novel selective JAK2 inhibitor, in a mouse model of colitis-induced colorectal cancerMatthew M Seavey, Lily D Lu, Kristine L Stump, et al.
Alimentary Pharmacology & Therapeutics|October 5, 2019
Raised serum Interleukin-6 identifies patients with liver cirrhosis at high risk for overt hepatic encephalopathyChristian Labenz, Gerrit Toenges, Yvonne Huber, et al.
Clinical and Translational Gastroenterology|June 23, 2020
Outcome Prediction of Covert Hepatic Encephalopathy in Liver Cirrhosis: Comparison of Four Testing StrategiesChristian Labenz, Gerrit Toenges, Jörn M Schattenberg, et al.
Plos One|March 19, 2016
The Impact of Liver Cell Injury on Health-Related Quality of Life in Patients with Chronic Liver DiseaseYvonne Alt, Anna Grimm, Liesa Schlegel, et al.
The American Journal of Gastroenterology|March 9, 2019
Development and Validation of a Prognostic Score to Predict Covert Hepatic Encephalopathy in Patients With CirrhosisChristian Labenz, Gerrit Toenges, Yvonne Huber, et al.
AIDS Care|September 26, 2001
Cost-effectiveness of prevention referrals for high-risk HIV-negatives in San FranciscoK S Heumann, R Marx, S J Lawrence, et al.
The Journal of Pharmacology and Experimental Therapeutics|October 31, 2007
Atrial antifibrillatory effects of structurally distinct IKur blockers 3-[(dimethylamino)methyl]-6-methoxy-2-methyl-4-phenylisoquinolin-1(2H)-one and 2-phenyl-1,1-dipyridin-3-yl-2-pyrrolidin-1-yl-ethanol in dogs with underlying heart failureChristopher P Regan, Laszlo Kiss, Gary L Stump, et al.
Pageof 40